Orelabrutinib demonstrated outstanding efficacy and well-tolerated safety profile in patients with SLE who had received 48 weeks of treatment in the phase IIb study. A total of 187 patients were enrolled and randomized (1:1:1) into three groups: orelabrutinib 75 mg once-daily (QD), orelabrutinib 50 mg QD, and placebo. Read More
Source link
NASA Artemis II crew speaks on upcoming lunar launch
IE 11 is not supported. For an optimal experience visit our site on another browser. Now Playing NASA Artemis II crew speaks on upcoming lunar launch 01:22 UP NEXT Officer…




